Karan Sood

Karan Sood

Auto-generated profile, based on publicly available information

Karan Sood

Department of Medical Oncology, Tata Memorial Hospital, Mumbai, Maharashtra, India

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2026 in JCO Global Oncology
Verified
Journal Article
Closed access
KSKaran Sood
Karan Sood
AAAmol Akhade
Amol Akhade
DSDr Nihanthy D S
Dr Nihanthy D S
SSSakshi Shimpi
Sakshi Shimpi
PURPOSE: In low- and middle-income countries (LMICs), access to traditional oncology education through conferences, journals, and in-person mentorship is often restricted. Social media has emerged as a potential tool to bridge this gap; however, its educational and clinical influence on oncology professionals remains underexplored. METHODS: We conducted a cross-sectional, anonymized, web-based survey of 202 oncology professionals from 13 countries. A 30-item questionnaire was used for the survey. Data were analyzed using descriptive statistics and chi-square tests. RESULTS: Among the respondents, 93% practiced in India, with 61% identifying Twitter (X) as their primary oncology information source. Daily engagement was reported by 53% of the respondents. The most valued benefits were early access to emerging research (30%) and trial updates (29%). Social media discussions atleast moderately influenced clinical decision making in 75% of respondents, with 29% reporting a substantial impact, which was a subjective assessment of the participants. Virtual tumor boards engaged 58% of the participants and prompted practice changes in 21%. Sixty-eight percent credited social media, with expanding their professional networks, and 25% initiated research collaborations through these platforms. Structured digital literacy training and tools, such as automated fact-checking and professional credential verification, were supported by over two thirds of the participants. CONCLUSION: Social media has become an essential educational and collaborative platform for oncology professionals, particularly in LMICs. By enabling timely access to research and supporting peer learning, it complements the traditional modes of oncology education. The formal integration of digital literacy training and content-verification mechanisms may enhance its safe and equitable use.

16 July 2026 in Indian Journal of Medical and Paediatric Oncology
Verified
Journal Article
Open access
KSKaran Sood
Karan Sood
PTPratiksha Tyagi
Pratiksha Tyagi

24 October 2024 in JMIR Preprints
Verified
Preprint
Open access
KSKaran Sood
Karan Sood
PTPratiksha Tyagi
Pratiksha Tyagi
ADAmol Dongre
Amol Dongre
BACKGROUND Triple-negative breast cancer (TNBC) is a highly malignant subtype of breast cancer characterized by the absence of estrogen, progesterone, and HER2/neu receptors. It is often associated with poor prognosis, high recurrence rates, and limited treatment options. Neoadjuvant chemotherapy (NACT) has been a cornerstone in the management of TNBC, yet the addition of carboplatin-a platinum-based agent-has shown promise in enhancing pathological complete response (pCR) rates and event-free survival (EFS) in various studies. OBJECTIVE • To assess event free survival in patients receiving carboplatin in addition to standard chemotherapy. • To determine the pathological complete response after neoadjuvant chemotherapy METHODS This study aims to evaluate the efficacy of incorporating carboplatin into standard NACT regimens for TNBC, focusing on its impact on pCR rates and DFS among patients in a rural setting in central India. This prospective observational study will include 39 patients diagnosed with stage II and III non-metastatic TNBC. Participants will receive a regimen of Adriamycin and cyclophosphamide followed by Paclitaxel and carboplatin. The study will assess pCR rates and DFS. Patients will be monitored for clinical and radiological responses, with evaluations performed using RECIST criteria. This study will provide valuable insights into the role of carboplatin in enhancing the efficacy of NACT for TNBC. RESULTS This study is poised to make a substantial contribution to the current body of knowledge concerning the management of triple negative breast cancer by enhancing the neoadjuvant therapy. This is an ongoing study protocol, and the results are going to be collected and analyzed in mid 2025. CONCLUSIONS Our study aims to treat patients with TNBC in a rural central Indian tertiary care hospital by starting with AC regimen followed by Paclitaxel and carboplatin as a neoadjuvant treatment. This study will help in representing this specific demographic population for early therapy enhancement and getting better survival in this subset of breast cancer. By employing a rigorous methodology, we strive to provide robust evidence on which intervention will offer superior outcomes in terms of pathological complete response and disease free interval. The findings from this trial are expected to inform clinical practice by guiding healthcare providers in selecting the most effective therapeutic approach for managing triple negative breast cancer, potentially improving patient outcomes in this patient population. CLINICALTRIAL Trial Registration Clinical Trials Registry of India CTRI/2023/11/059751 https://ctri.nic.in/Clinicaltrials/pmaindet2.php?EncHid=OTUwODc=&Enc=68268.24470&userName=059751

18 November 2024 in JMIR Preprints
Verified
Preprint
Open access
KSKaran Sood
Karan Sood
PTPratiksha Tyagi
Pratiksha Tyagi
ADAmol Dongre
Amol Dongre
UNSTRUCTURED Aging is an inevitable and universal phenomenon characterized by the decline of physiological systems, making organisms more vulnerable to a variety of age-related diseases. This decline is driven by cumulative cellular damage, oxidative stress, inflammation, and impaired cellular repair mechanisms, leading to increased fragility of tissues and organs. Cardiovascular diseases, such as coronary artery disease, hypertension, and strokes, are particularly common in the elderly, often resulting from atherosclerosis. Neurodegenerative diseases like Alzheimer's and Parkinson's, which involve the progressive loss of neurons, also significantly impact cognitive function and motor coordination in aging populations. Metabolic disorders, including type 2 diabetes and osteoporosis, are closely associated with aging. Type 2 diabetes impairs glucose regulation, while osteoporosis reduces bone density, increasing the risk of fractures. These conditions, along with cancer, arthritis, macular degeneration, and hearing loss, contribute to the overall decline in physical and cognitive function as individuals age. Although aging and its associated disorders cannot be entirely prevented, researchers are focused on understanding the underlying mechanisms to develop treatments that promote healthy aging. Personalized therapies, genetic medicine, biotechnology, regular exercise, a balanced diet, and social engagement are recognized as essential strategies for maintaining health and well-being into old age. In response to the challenges posed by aging, Google launched Calico (California Life Company) in 2013, aiming to improve health during the final years of life by exploring the biology of aging and developing therapies to combat age-related diseases. Led by Arthur D. Levinson, Calico’s research strategy includes large-scale genomic and proteomic studies, as well as the use of model organisms to identify key biochemical processes involved in aging. The company is actively developing therapies for cancer, neurological diseases, cardiovascular conditions, and other age-related disorders through collaborations with academic institutions and biotech companies. Calico also utilizes data analytics and machine learning to identify biomarkers of aging, discover new therapeutic targets, and predict individual responses to treatments. This data-driven approach accelerates the discovery process in aging biology and helps prioritize research initiatives. While the goal of achieving immortality remains out of reach, Calico's efforts align with the principles of promoting healthy aging and extending the health span, positioning the company at the forefront of longevity research and offering significant promise for transforming the aging experience.

6 July 2026 in Indian Journal of Medical and Paediatric Oncology
Verified
Journal Article
Open access
PDF file
KSKaran Sood
Karan Sood
PKPadmaj Kulkarni
Padmaj Kulkarni
Violence against physicians in India is no longer an occasional law and order issue. This signals deep-seated failures in health system design, governance, and accountability. Indian commentaries and reviews describe this pattern as an epidemic of violence against doctors, with implications for morale, retention, and care quality. Institutional Review Board approval was not required. Patient consent was not required as there were no patients in this study. Article published online: 06 July 2026 © 2026. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/) Thieme Medical and Scientific Publishers Private Limited A-13A, Graphix Tower 1, 6th floor, Sector 62, Noida 201309, Uttar Pradesh, India

1 April 2025 in Multidisciplinary Science Journal
Verified
Journal Article
Open access
PDF file
KSKaran Sood
Karan Sood
PTPratiksha Tyagi
Pratiksha Tyagi
ADAmol Dongre
Amol Dongre
Mesenteric leiomyosarcoma (M-LMS) is a rare malignancy arising from smooth muscle cells that often presents with nonspecific symptoms, making early diagnosis challenging. While LMS are known to develop in retroperitoneal or pelvic regions, their occurrence in the mesentery is exceptionally uncommon. This case report discusses the presentation, diagnosis, and management of mesenteric root LMS in a 40-year-old female, highlights the complexities associated with this rare disease. The patient presented with generalized weakness for five years and lower abdominal pain for one year. Physical examination revealed pallor, and blood tests revealed anemia. Imaging studies revealed a large lobulated mass in the abdomen, which was surgically resected. Histopathological analysis confirmed the diagnosis of a high-grade spindle cell tumor, specifically M-LMS, with negative CD117 staining and positive smooth muscle actin (SMA) staining. The patient underwent completion radical surgery with resection and anastomosis of the small intestine and was treated with adjuvant chemotherapy. The patient demonstrated excellent clinical response and remained disease-free for 10 years following surgery and chemotherapy. Mesenteric M-LMS is a rare subtype of soft tissue sarcoma (STS) that is often asymptomatic until advanced stages. The diagnosis is often delayed owing to its nonspecific presentation, such as abdominal pain, weakness, or anemia, as observed in this case. Histopathologically, LMS is characterized by spindle cells arranged in fascicles, displaying nuclear pleomorphism, high mitotic activity, and areas of necrosis. Immunohistochemistry (IHC) is crucial for distinguishing LMS from other spindle cell tumors, such as gastrointestinal stromal tumors (GISTs), which express CD117 and DOG1. In contrast, LMS stains positive for smooth muscle markers such as desmin, caldesmon, and SMA. Genetic mutations, such as the loss of the tumor suppressors TP53 and RB1 and the dysregulation of the PI3K/AKT/mTOR pathway, play critical roles in the pathogenesis of LMS. Surgical resection remains the mainstay of treatment, with adjuvant chemotherapy showing modest efficacy in preventing recurrence. However, high-grade tumors and large tumors pose significant risks for recurrence and metastasis. M-LMS is a rare but aggressive neoplasm with a poor prognosis if not treated aggressively. Early recognition, radical surgical resection, and adjuvant chemotherapy are essential for long-term survival. This case highlights the importance of a multidisciplinary approach, individualized treatment plans, and regular follow-up for the early detection of recurrence.